Eton Pharmaceuticals, Inc.
ETON
$17.29
-$0.17-0.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 85.40% | 40.88% | 23.29% | 5.64% | 8.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 85.40% | 40.88% | 23.29% | 5.64% | 8.14% |
| Cost of Revenue | 76.26% | 73.22% | 47.43% | 56.18% | 67.04% |
| Gross Profit | 91.63% | 24.39% | 11.16% | -13.56% | -12.80% |
| SG&A Expenses | 54.88% | 40.60% | 18.00% | 10.17% | 6.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.34% | 48.63% | 25.46% | 28.85% | 27.64% |
| Operating Income | 112.99% | -441.70% | -83.05% | -380.14% | -1,196.69% |
| Income Before Tax | 36.94% | -487.50% | -452.69% | -337.72% | -2,629.06% |
| Income Tax Expenses | -66.45% | -63.97% | -93.93% | -- | -- |
| Earnings from Continuing Operations | 38.27% | -602.08% | -308.44% | -345.56% | -2,757.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.27% | -602.08% | -308.44% | -345.56% | -2,757.69% |
| EBIT | 112.99% | -441.70% | -83.05% | -380.14% | -1,196.69% |
| EBITDA | 163.91% | -99.79% | -208.94% | -254.96% | -1,859.60% |
| EPS Basic | 40.95% | -580.00% | -309.39% | -343.87% | -2,445.10% |
| Normalized Basic EPS | 64.19% | -439.37% | -392.81% | -335.90% | -2,360.32% |
| EPS Diluted | 36.43% | -610.41% | -340.06% | -350.97% | -2,464.71% |
| Normalized Diluted EPS | 64.00% | -460.52% | -351.37% | -344.97% | -1,790.24% |
| Average Basic Shares Outstanding | 2.73% | 1.83% | 0.97% | 0.94% | 1.12% |
| Average Diluted Shares Outstanding | 3.36% | 2.08% | 1.22% | 0.89% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |